It was reported on Thursday that Hikma Pharmaceuticals USA Inc, a subsidiary of Hikma Pharmaceuticals PLC, has introduced Dicyclomine Hydrochloride Oral Solution, USP, 10mg/5 mL, an AA-rated version of Bentyl1 Oral Syrup, 10mg/5 mL, in the United States.

The United States Food and Drug Administration approved the product with a Competitive Generic Therapy designation. The company is the 'first approved applicant' for this CGT and is thus eligible for 180 days of CGT exclusivity that started upon commercial marketing of the company's product.

The product is to treat patients with functional bowel/irritable bowel syndrome.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE